Editorial explainers for a skeptical audience
The learn section is where Peptide Daily earns trust: not through volume, but through clean typography, cited context, and clear signals about what is approved, investigational, or still firmly in research territory.
Core guides for navigating the platform
How to evaluate a peptide vendor
Use vendor profiles, Finnrick grades, and testing depth to compare suppliers without relying on affiliate-style hype.
How Peptide Daily scores trust
See how lab quality, evidence depth, and recency feed into the site’s visible trust signals and methodology.
Why research news matters
Follow regulatory shifts, published studies, and clinical programs so the pricing layer sits inside real scientific context.
Metabolic / GLP-1 guides
Each guide keeps the same editorial frame: what the peptide is, how the evidence base looks, and what the regulatory context does and does not allow.
Tirzepatide
Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist (Mounjaro, Zepbound) studied for type 2 diabetes and chronic weight management, with extensive Phase 3 trial data. FDA Approved.
Semaglutide
Semaglutide is an FDA-approved GLP-1 receptor agonist (Ozempic, Wegovy) with robust clinical evidence for type 2 diabetes management and chronic weight loss. FDA Approved.
Retatrutide
Retatrutide is an investigational triple GLP-1/GIP/glucagon receptor agonist in Phase 3 TRIUMPH trials, demonstrating significant weight reduction in Phase 2 research. Investigational.
Mazdutide
Mazdutide is a dual GLP-1/glucagon receptor agonist approved in China for weight management and T2D; currently in Phase 2 US trials. Not FDA-approved. Approved in China.
Survodutide
Survodutide (BI 456906) is an investigational dual GLP-1/glucagon receptor agonist in Phase 3 trials for obesity and MASH; not yet approved by any regulatory authority. Investigational.
Cagrilintide
Cagrilintide is a long-acting amylin analog studied in combination with semaglutide (CagriSema) in Phase 3 REDEFINE trials. It is not yet approved by any regulatory authority. Investigational.
Tissue Repair guides
Each guide keeps the same editorial frame: what the peptide is, how the evidence base looks, and what the regulatory context does and does not allow.
BPC-157
BPC-157 is a synthetic gastric peptide extensively studied in animal models for tissue repair and gut healing. It has no completed human trials and is classified as an FDA Category 2 bulk drug substance. Research Chemical.
TB-500
TB-500 is a synthetic fragment of thymosin beta-4, studied in preclinical and veterinary settings for tissue repair. It is not FDA-approved for human use and is WADA-prohibited. Research Chemical.
GHK-Cu
GHK-Cu is a naturally occurring copper-binding tripeptide researched for collagen synthesis and wound healing. Topical forms appear in many cosmetic products; injectable use is not FDA-approved. Research Chemical.
Growth Hormone guides
Each guide keeps the same editorial frame: what the peptide is, how the evidence base looks, and what the regulatory context does and does not allow.
CJC-1295
CJC-1295 is a GHRH analog that stimulates pituitary GH release. Limited human clinical data exists; it is not FDA-approved and is classified as a compounding safety concern. Research Chemical.
Ipamorelin
Ipamorelin is a selective growth hormone secretagogue that triggers pulsatile GH release without significant cortisol or prolactin elevation. Not FDA-approved; WADA-prohibited. Research Chemical.
Sermorelin
Sermorelin (GHRH 1-29) was previously FDA-approved for pediatric GH deficiency and is now available through compounding. It stimulates pituitary GH release and has a longer clinical history than most research peptides. Compounded (Rx).
Tesamorelin
Tesamorelin (Egrifta) is an FDA-approved GHRH analog indicated for HIV-associated lipodystrophy. It stimulates endogenous GH release and has Phase 3 trial data supporting its approved use. FDA Approved.
Melanocortin guides
Each guide keeps the same editorial frame: what the peptide is, how the evidence base looks, and what the regulatory context does and does not allow.
Melanotan II
Melanotan II is a non-selective melanocortin receptor agonist studied for skin tanning and sexual function. It has never been approved by the FDA; multiple regulatory agencies have issued safety warnings. Research Chemical.
PT-141
PT-141 (bremelanotide / Vyleesi) is an FDA-approved melanocortin agonist for HSDD in premenopausal women. It targets CNS receptors influencing sexual desire rather than vascular pathways. FDA Approved.
Research information only
Peptide Daily is an informational resource only. Peptide research chemicals are not approved for human use by the FDA unless otherwise noted. Nothing on this site constitutes medical advice. Consult a qualified healthcare provider before using any peptide or research chemical.